Prescient Therapeutics LimitedASX: PTX

PTX-100 Ph1b results show excellent safety & efficacy in TCL

· Issued by Prescient Therapeutics Limited

Filed with ASX · · 6 pages · English

Summary by 6ix AI

The study successfully met its primary objectives, showing no drug-related serious adverse events and preliminary efficacy exceeding standard care expectations. Clinical responses were observed in a significant portion of assessable patients, with an impressive median progression-free survival reported.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Prescient Therapeutics Limited on 6ix

Earlier from Prescient Therapeutics

Later from Prescient Therapeutics

All Prescient Therapeutics news releases